CTLA4 and neoplasm: In conclusion, these findings demonstrate that there is a wide range of ICs expressed in OAC patients that represent potential therapeutic targets, outside of the well-known PD-1 and CTLA-4 axis, to propagate immune responses promoting tumour eradication.